The 2022 revision of the PIC/S Guide to GMP for Medicinal Products (PE 009-17) Annex 1 is expected to be adopted by the Therapeutic Goods Administration (TGA) in 2025 and Contamination Control Strategy (CCS) has emerged as a key new requirement. While CCS under Annex 1 is central for sterile drug manufacturers, it is also applicable for...
